rna
interfer
rnai
potent
specif
posttranscript
gene
silenc
process
sinc
discoveri
tremend
effort
made
translat
rnai
technolog
therapeut
applic
treatment
differ
human
diseas
includ
respiratori
diseas
manipul
express
diseaseassoci
gene
similar
nucleic
acidbas
therapeut
major
hurdl
rnai
therapi
deliveri
pulmonari
deliveri
promis
approach
deliv
rnai
therapeut
directli
airway
treat
local
condit
minim
system
side
effect
noninvas
rout
administr
gener
well
accept
patient
howev
pulmonari
drug
deliveri
challeng
lung
pose
seri
anatom
physiolog
immunolog
barrier
drug
deliveri
understand
barrier
essenti
develop
effect
rna
deliveri
system
review
differ
barrier
pulmonari
drug
deliveri
introduc
potenti
rnai
molecul
new
class
therapeut
latest
preclin
clinic
studi
use
rnai
therapeut
differ
respiratori
condit
discuss
detail
hope
review
provid
use
insight
move
inhal
rnai
therapeut
bench
bedsid
lung
diseas
among
lead
caus
death
worldwid
current
treatment
lung
diseas
lung
cancer
respiratori
infect
inflammatori
diseas
pulmonari
fibrosi
limit
efficaci
almost
two
decad
ago
doublestrand
rna
dsrna
discov
play
import
role
regul
gene
function
sequencespecif
posttranscript
gene
silenc
mechan
call
rna
interfer
rnai
therapeut
potenti
rnai
soon
realiz
present
new
power
approach
treat
prevent
mani
diseas
includ
respiratori
disord
modul
gene
express
rnai
mediat
variou
type
rna
molecul
includ
long
dsrna
short
interf
rna
sirna
short
hairpin
rna
shrna
microrna
mirna
mechan
rnai
illustr
figur
gener
properti
differ
type
rnai
molecul
summar
tabl
long
dsrna
around
nucleotid
length
employ
studi
gene
function
exogen
dsrna
introduc
cytoplasm
cell
cleav
rnase
iii
enzym
dicer
short
dsrna
call
sirna
sirna
nucleotid
length
load
protein
complex
call
rnainduc
silenc
complex
risc
sirna
unwound
sens
strand
also
known
passeng
strand
sirna
degrad
wherea
remain
antisens
strand
also
known
guid
strand
guid
activ
ric
target
messeng
rna
mrna
full
complementari
bind
mrna
cleav
argonaut
risc
lead
silenc
target
gene
sinc
long
dsrna
known
trigger
immunostimulatori
respons
activ
dicerrel
antivir
pathway
induct
type
interferon
ifn
less
suitabl
therapeut
use
contrast
synthet
sirna
promis
gene
silenc
mediat
lower
risk
immun
respons
also
wide
investig
rnai
molecul
therapeut
applic
clinic
trial
studi
initi
sinc
shrna
sequenc
rna
transcrib
nucleu
cell
dna
vector
either
rna
polymeras
ii
iii
primari
transcript
call
primari
shrna
prishrna
contain
hairpin
like
stemloop
structur
prishrna
process
nucleotid
long
loopstem
precursor
shrna
preshrna
protein
complex
contain
rnase
iii
nucleas
drosha
dsrna
bind
domain
protein
transport
cytoplasm
special
nuclear
membran
protein
loop
sequenc
preshrna
cleav
dicer
form
doublestrand
sirna
endogen
produc
sirna
load
risc
induc
rnai
similar
process
synthet
sirna
sinc
shrna
express
unit
incorpor
viral
vector
continu
synthes
host
cell
induc
longlast
gene
silenc
effect
riscload
process
shrna
ten
time
effici
sirna
implic
lower
dose
shrna
requir
maintain
therapeut
efficaci
less
offtarget
effect
howev
shrna
approach
dnabas
strategi
depend
express
shrna
encod
gene
often
requir
viral
vector
deliveri
perspect
introduct
synthet
sirna
cytoplasm
straightforward
way
induc
rnai
use
viral
vector
deliveri
pose
safeti
concern
therapeut
applic
mirna
natur
occur
noncod
rna
play
key
role
regul
gene
express
primari
mirna
primirna
transcrib
rna
polymeras
ii
endogen
mirna
gene
nucleu
hairpincontain
primirna
structur
similar
prishrna
therefor
matur
pathway
mirna
also
similar
shrna
primrna
convert
complex
precursor
mirna
premirna
contain
nucleotid
interspers
mismatch
adopt
loop
structur
premirna
subsequ
transport
cytoplasm
process
dicer
matur
mirna
nucleotid
length
oppos
sirna
antisens
strand
mirna
partial
complementari
target
mrna
lead
gene
silenc
via
translat
repress
andor
mrna
deadenyl
posit
end
mirna
seed
sequenc
essenti
target
recognit
mirna
bind
site
mrna
locat
untransl
region
utr
two
major
approach
mirnabas
therapeut
mirna
inhibit
suppress
action
endogen
mirna
antisens
oligonucleotid
antimir
ii
mirna
replac
introduc
synthet
mirna
mirna
mimic
restor
function
endogen
mirna
latter
discuss
review
compar
sirnabas
therapeut
mirna
potenti
target
multipl
gene
due
imperfect
bind
target
mrna
rnai
therapeut
offer
sever
advantag
tradit
small
molecul
proteinbas
drug
could
virtual
target
gene
high
select
includ
undrugg
target
design
synthesi
rnai
molecul
rel
simpl
need
cellular
express
system
complex
protein
purif
refold
scheme
compar
antisens
oligonucleotid
rnai
potent
specif
despit
huge
therapeut
potenti
deliveri
remain
major
barrier
clinic
applic
rnai
therapeut
treatment
respiratori
disord
pulmonari
rout
administr
deliv
rnai
molecul
directli
site
action
therebi
lower
dose
requir
minim
system
advers
effect
rnai
molecul
also
avoid
rapid
clearanc
serum
nucleas
bloodstream
moreov
inhal
noninvas
rout
administr
easili
accept
patient
compar
parenter
administr
lead
better
patient
complianc
howev
pulmonari
drug
deliveri
challeng
sever
key
biolog
barrier
highlight
figur
rnai
therapeut
offer
sever
advantag
tradit
small
molecul
proteinbas
drug
could
virtual
target
gene
high
select
includ
undrugg
target
design
synthesi
rnai
molecul
rel
simpl
need
cellular
express
system
complex
protein
purif
refold
scheme
compar
antisens
oligonucleotid
rnai
potent
specif
despit
huge
therapeut
potenti
deliveri
remain
major
barrier
clinic
applic
rnai
therapeut
treatment
respiratori
disord
pulmonari
rout
administr
deliv
rnai
molecul
directli
site
action
therebi
lower
dose
requir
minim
system
advers
effect
rnai
molecul
also
avoid
rapid
clearanc
serum
nucleas
bloodstream
moreov
inhal
noninvas
rout
administr
easili
accept
patient
compar
parenter
administr
lead
better
patient
complianc
howev
pulmonari
drug
deliveri
challeng
sever
key
biolog
barrier
highlight
figur
human
respiratori
tract
divid
conduct
region
nasal
caviti
pharynx
trachea
bronchi
bronchiol
respiratori
region
respiratori
bronchiol
alveoli
former
pathway
gase
conduct
wherea
latter
site
gaseou
exchang
extens
branch
structur
airway
vari
length
diamet
present
primari
hurdl
pulmonari
drug
deliveri
mechan
inhal
particl
deposit
lung
includ
inerti
impact
gravit
sediment
diffus
intercept
electrostat
precipit
illustr
figur
first
three
mechan
major
mechan
greatli
influenc
aerodynam
size
particl
optim
particl
size
lung
deposit
larger
particl
like
impact
trap
upper
airway
wall
bifurc
small
particl
easili
exhal
normal
breath
smaller
particl
nm
may
success
deposit
alveolar
space
increas
diffusion
mobil
howev
aerosol
nm
difficult
produc
make
applic
less
favor
human
respiratori
tract
divid
conduct
region
nasal
caviti
pharynx
trachea
bronchi
bronchiol
respiratori
region
respiratori
bronchiol
alveoli
former
pathway
gase
conduct
wherea
latter
site
gaseou
exchang
extens
branch
structur
airway
vari
length
diamet
present
primari
hurdl
pulmonari
drug
deliveri
mechan
inhal
particl
deposit
lung
includ
inerti
impact
gravit
sediment
diffus
intercept
electrostat
precipit
illustr
figur
first
three
mechan
major
mechan
greatli
influenc
aerodynam
size
particl
optim
particl
size
lung
deposit
larger
particl
like
impact
trap
upper
airway
wall
bifurc
small
particl
easili
exhal
normal
breath
smaller
particl
nm
may
success
deposit
alveolar
space
increas
diffusion
mobil
howev
aerosol
nm
difficult
produc
make
applic
less
favor
presenc
fluid
layer
airway
includ
mucu
pulmonari
surfact
also
creat
barrier
deliveri
drug
molecul
lung
mucu
gel
threedimension
network
structur
act
siev
filter
larg
molecul
nm
mucin
major
compon
mucu
contain
hydrophil
glycosyl
residu
rich
serin
threonin
hydrophob
nonglycosyl
cysteinerich
domain
characterist
allow
electrostat
hydrophil
hydrophob
interact
mucu
drug
particl
sinc
mucu
continu
produc
shed
replac
togeth
mucociliari
clearanc
action
fast
turnov
rate
mucu
lead
rapid
clearanc
entrap
drug
molecul
prevent
reach
epithelium
moreov
cough
clearanc
occur
mucu
reach
throat
anoth
remov
mechan
rnai
molecul
airway
hand
role
pulmonari
surfact
nucleic
acid
deliveri
controversi
pulmonari
surfact
compos
approxim
lipid
protein
suggest
lipid
protein
lung
surfact
interact
nonvir
cation
lipidbas
deliveri
system
lead
prematur
releas
nucleic
acid
convers
polymerbas
deliveri
system
found
compat
pulmonari
surfact
commerci
pulmonari
surfact
employ
prepar
polymer
nanoparticl
facilit
cellular
uptak
sirna
improv
gene
silenc
effect
apart
physic
barrier
rnai
molecul
may
undergo
enzymat
degrad
follow
pulmonari
deliveri
rna
extrem
suscept
nucleas
activ
nake
sirna
short
halflif
less
min
serum
due
lack
serum
lung
halflif
unmodifi
sirna
airway
reach
three
hour
mous
rnai
molecul
may
also
taken
remov
alveolar
macrophag
upon
lung
deposit
alveolar
macrophag
respons
engulf
digest
foreign
particl
lower
airway
via
phagocytosi
unless
target
rnai
molecul
locat
insid
macrophag
mycobacterium
tuberculosi
caus
agent
tuberculosi
typic
resid
alveolar
macrophag
otherwis
rnai
molecul
subject
degrad
insid
macrophag
reach
target
site
presenc
fluid
layer
airway
includ
mucu
pulmonari
surfact
also
creat
barrier
deliveri
drug
molecul
lung
mucu
gel
threedimension
network
structur
act
siev
filter
larg
molecul
nm
mucin
major
compon
mucu
contain
hydrophil
glycosyl
residu
rich
serin
threonin
hydrophob
nonglycosyl
cysteinerich
domain
characterist
allow
electrostat
hydrophil
hydrophob
interact
mucu
drug
particl
sinc
mucu
continu
produc
shed
replac
togeth
mucociliari
clearanc
action
fast
turnov
rate
mucu
lead
rapid
clearanc
entrap
drug
molecul
prevent
reach
epithelium
moreov
cough
clearanc
occur
mucu
reach
throat
anoth
remov
mechan
rnai
molecul
airway
hand
role
pulmonari
surfact
nucleic
acid
deliveri
controversi
pulmonari
surfact
compos
approxim
lipid
protein
suggest
lipid
protein
lung
surfact
interact
nonvir
cation
lipidbas
deliveri
system
lead
prematur
releas
nucleic
acid
convers
polymerbas
deliveri
system
found
compat
pulmonari
surfact
commerci
pulmonari
surfact
employ
prepar
polymer
nanoparticl
facilit
cellular
uptak
sirna
improv
gene
silenc
effect
apart
physic
barrier
rnai
molecul
may
undergo
enzymat
degrad
follow
pulmonari
deliveri
rna
extrem
suscept
nucleas
activ
nake
sirna
short
halflif
less
min
serum
due
lack
serum
lung
halflif
unmodifi
sirna
airway
reach
three
hour
mous
rnai
molecul
may
also
taken
remov
alveolar
macrophag
upon
lung
deposit
alveolar
macrophag
respons
engulf
digest
foreign
particl
lower
airway
via
phagocytosi
unless
target
rnai
molecul
locat
insid
macrophag
mycobacterium
tuberculosi
caus
agent
tuberculosi
typic
resid
alveolar
macrophag
otherwis
rnai
molecul
subject
degrad
insid
macrophag
reach
target
site
rnai
molecul
overcom
aforement
extracellular
barrier
reach
target
cell
need
overcom
set
intracellular
barrier
ultim
site
action
depend
type
rnai
molecul
synthet
sirna
mirna
mimic
need
reach
cytoplasm
risc
locat
wherea
dna
encod
shrna
mirna
need
enter
nucleu
order
transcript
take
place
surfac
adhes
first
step
cellular
entri
variou
endocyt
mechan
involv
cellular
uptak
macromolecul
subsequ
influenc
intracellular
traffick
deliveri
effici
clathrindepend
endocytosi
common
rout
cellular
entri
macromolecul
follow
cell
entri
rnai
molecul
entrap
earli
endosom
progress
acidif
occur
late
endosom
fuse
lysosom
contain
hydrolas
degrad
rnai
molecul
rnai
molecul
must
escap
endosom
earli
stage
exert
biolog
effect
strategi
endosom
escap
review
literatur
shrna
mirna
vector
nuclear
entri
addit
barrier
particularli
challeng
due
presenc
nuclear
membran
imperm
substanc
except
small
nonpolar
molecul
nonvir
vector
ineffici
deliv
dna
nucleu
virus
evolv
transport
genom
nucleu
henc
becom
attract
dna
carrier
improv
transduct
effici
howev
poor
safeti
profil
high
product
cost
risk
immunogen
limit
applic
viral
vector
mediat
rnai
laboratori
tool
deliveri
vector
carrier
gener
necessari
overcom
aforement
barrier
promot
cellular
uptak
offer
protect
rnai
molecul
rnai
deliveri
system
categor
viral
nonvir
vector
accord
natur
deliveri
system
extens
review
viral
vector
refer
use
virus
deliv
genet
materi
cell
extrem
effici
transduc
cell
provid
either
transient
longterm
gene
express
depend
type
virus
employ
vivo
studi
use
adenovirus
adenoassoci
viru
aav
retrovirus
express
plasmid
dna
encod
shrna
mirna
induc
rnai
attract
properti
viral
vector
abil
access
nucleu
cell
thu
high
efficaci
express
rna
subsequ
regul
gene
express
howev
clinic
applic
viral
vector
limit
toxic
insert
mutagenesi
associ
retrovirus
immunogen
associ
adenovirus
addit
smaller
size
avv
limit
amount
therapeut
gene
insert
compar
viral
vector
nonvir
vector
gener
better
safeti
profil
lower
product
cost
investig
pulmonari
deliveri
rnai
molecul
lipidbas
polymerbas
peptidebas
three
major
nonvir
deliveri
system
lipidbas
vector
commonli
use
vector
rnai
deliveri
includ
cation
liposom
solid
lipid
nanoparticl
solid
nanostructur
lipid
carrier
lipidoid
phrespons
lipid
mani
commerci
avail
transfect
agent
ie
lipofectamin
oligofectamin
transittko
dharmafect
lipidbas
system
despit
promis
transfect
efficaci
major
challeng
use
lipid
immun
respons
cytotox
addit
lipid
biocompat
biodegrad
natur
polym
chitosan
dextran
well
synthet
polym
poli
lacticcoglycol
acid
plga
polyethylenimin
pei
pamam
dendrim
use
prepar
polymer
nanoparticl
rna
deliveri
polym
rel
low
toxic
compar
lipidbas
vector
versatil
chemic
modif
peptidebas
deliveri
system
peptid
poli
llysin
pll
cell
penetr
peptid
cpp
phrespons
peptid
investig
deliveri
rnai
molecul
differ
type
peptid
mediat
cellular
transfect
via
differ
mechan
facilit
cellular
uptak
promot
endosom
escap
peptid
use
carri
rnai
molecul
alon
act
function
compon
carrier
current
effici
peptid
low
toxic
high
transfect
efficaci
still
develop
note
pulmonari
deliveri
reduc
nucleas
activ
lung
make
success
deliveri
unmodifi
nake
rna
becom
possibl
howev
mechan
nake
sirna
could
overcom
extracellular
intracellular
barrier
follow
pulmonari
administr
still
remain
understood
therapeut
potenti
rnaibas
therapi
target
respiratori
disord
wide
explor
past
decad
follow
section
preclin
clinic
studi
involv
deliveri
rnai
molecul
airway
treatment
lung
diseas
discuss
lung
cancer
lead
caus
cancer
death
world
mainstay
treatment
chemotherapi
indic
around
newli
diagnos
patient
local
advanc
metastat
diseas
treatment
option
includ
surgeri
radiotherapi
angiogenesi
inhibitor
epiderm
growth
factor
receptor
egfr
inhibitor
new
medic
licens
treatment
lung
cancer
despit
variou
treatment
option
prognosi
lung
cancer
poor
major
problem
chemotherapi
toxic
lack
specif
drug
resist
recent
year
pulmonari
deliveri
rnai
molecul
explor
new
treatment
lung
cancer
gene
associ
tumor
cell
growth
drug
resist
potenti
target
tabl
summar
recent
vivo
studi
pulmonari
rnai
deliveri
lung
cancer
treatment
gene
essenti
tumor
growth
progress
racalpha
serinethreonineprotein
kinas
b
cmyc
evalu
rnai
target
import
mediat
cell
growth
prolifer
surviv
nonsmal
cell
lung
cancer
nsclc
activ
pathway
observ
nsclc
patient
found
reduc
chemoand
radiationinduc
apoptosi
extend
surviv
tumor
cell
sorbitol
diacrylatepolyethylenimin
sdapei
employ
deliv
shrna
target
cdna
encod
program
cell
death
protein
dual
express
vector
via
pulmonari
rout
murin
lung
cancer
model
simultan
inhibit
overexpress
could
induc
potent
anticanc
effect
total
tumor
number
tumor
size
larger
mm
lung
significantli
reduc
eight
dose
glycerol
triacrylatespermin
gtspe
polyspermin
lentiviru
also
employ
carrier
shrna
target
signal
pathway
pulmonari
deliveri
although
repeat
aerosol
deliveri
lentiviralbas
shrna
achiev
potent
knockdown
target
inhal
procedur
gener
larg
number
viral
particl
safeti
concern
regard
use
viral
vector
inhal
includ
potenti
mutagen
immunogen
risk
aerosoltransmit
infect
therefor
aerosol
deliveri
rnai
molecul
use
viral
vector
must
go
vigor
biosafeti
evalu
clinic
use
note
aminoacyltrna
synthetas
ar
interact
multifunct
protein
lack
exon
racalpha
serinethreonineprotein
kinas
b
bcell
lymphoma
dox
doxorubicin
egfp
enhanc
green
fluoresc
protein
gptspe
glycerol
propoxyl
triacryl
spermin
gtspe
glycerol
triacrylatespermin
multidrug
resist
protein
sodiumdepend
phosphat
cotransport
program
cell
death
protein
pei
polyethylenimin
rgd
arginineglycineaspart
acid
peptid
ribophorin
ii
np
nanoparticl
sdapei
sorbitol
diacrylatepolyethylenimin
tax
paclitaxel
cmyc
oncogen
downstream
conduit
oncogen
signal
necessari
growth
control
differenti
apoptosi
abnorm
express
cmyc
associ
mani
tumor
deactiv
myc
efficaci
lung
tumor
therapi
cond
et
al
deliv
sirna
target
cmyc
lung
mous
use
rgdsurfacemodifi
gold
nanoparticl
aunp
intratrach
instil
rgd
peptid
argglyasp
cell
adhes
peptid
respons
mediat
cell
adhes
prolifer
bind
integrin
receptor
famili
specif
marker
angiogenesi
upregul
endothelium
strategi
success
suppress
cmyc
express
level
tumor
cell
prolifer
result
approxim
increas
surviv
orthograft
mous
tumor
model
gene
associ
mdr
also
evalu
target
rnai
ribophorin
ii
bcell
lymphoma
multidrug
resist
protein
known
associ
apoptosi
docetaxelresist
human
breast
cancer
cell
involv
nsclc
investig
recent
novel
rnai
molecul
pnkrna
target
develop
deliv
mice
bear
lung
cancer
intrapulmonari
deliveri
new
class
rnai
agent
uniqu
helic
structur
contain
central
stem
two
loop
claim
stabl
nucleas
degrad
inhibit
lung
tumor
growth
observ
without
sign
toxic
treatment
antitumor
effect
trigger
pnkrna
target
without
use
anticanc
drug
could
attribut
multipl
activ
antiapoptot
involv
regul
tumor
surviv
howev
mechan
nake
pnkrna
molecul
overcam
extracellular
intracellular
barrier
initi
rnai
elucid
besid
inhibit
mdr
associ
protein
alon
codeliveri
anticanc
drug
rnai
therapeut
altern
approach
tackl
mdr
variou
type
cancer
combin
therapi
offer
potenti
advantag
synergist
activ
overcom
drug
resist
reduc
side
effect
chemotherapi
main
player
nonpump
cellular
resist
respons
drug
efflux
cancer
cell
investig
combin
approach
taratula
et
al
prepar
lipidbas
nanoparticl
contain
sirna
target
well
anticanc
drug
doxorubicin
paclitaxel
nanoparticl
deliv
lung
tumor
mous
model
use
nose
exposur
chamber
inhal
almost
complet
disappear
lung
tumor
observ
anim
treat
paclitaxel
plu
sirna
contrast
treatment
paclitaxel
alon
slow
growth
tumor
xu
et
al
develop
polyethylenimin
pei
base
deliveri
system
simultan
deliv
sirna
target
doxorubicin
lung
mice
metastat
lung
cancer
synergist
antitumor
efficaci
achiev
compar
deliveri
doxorubicin
sirna
alon
studi
indic
suppress
resist
gene
rnai
molecul
via
inhal
could
restor
sensit
chemotherapeut
drug
lead
death
tumor
cell
respiratori
infect
caus
wide
rang
microorgan
airway
includ
bacteria
virus
one
common
reason
hospit
among
adult
due
rise
antimicrobi
resist
mani
infecti
diseas
includ
respiratori
infect
becom
difficult
treat
rnai
therapeut
appear
attract
approach
fight
infect
preclin
studi
rnai
therapeut
combat
respiratori
infect
summar
tabl
sinc
rnai
first
report
inhibit
respiratori
syncyti
viru
rsv
increas
number
studi
initi
explor
potenti
rnai
technolog
treat
respiratori
viral
infect
includ
influenza
sever
acut
respiratori
syndrom
sar
rnai
molecul
offer
sever
advantag
antivir
therapeut
specif
target
conserv
region
mrna
sequenc
viral
genom
make
effect
mutat
viral
strain
addit
rnai
molecul
design
rapidli
target
viral
gene
shorten
lead
time
develop
new
antivir
agent
particularli
use
respons
infect
outbreak
achiev
effect
antivir
effect
viral
target
must
essenti
pathogenesi
viral
infect
andor
replic
cycl
also
desir
target
gene
share
similar
conserv
sequenc
among
differ
strain
achiev
broad
viral
inhibit
furthermor
viral
gene
substanti
differ
human
gene
minim
undesir
side
effect
rsv
infect
one
common
infect
children
adult
rsv
infect
usual
lead
selflimit
upper
respiratori
ill
howev
sever
rsv
infect
observ
elderli
patient
lung
diseas
immunocompromis
patient
current
manag
rsv
includ
bronchodil
corticosteroid
antibiot
support
care
efficaci
satisfactori
date
licens
vaccin
avail
prevent
diseas
unmet
need
develop
effect
rsv
therapeut
vaccin
pediatr
adult
popul
bitko
et
al
report
inhibit
rsv
parainfluenza
viru
piv
replic
sirna
target
viral
phosphoprotein
p
protein
crucial
subunit
viral
rnadepend
rna
polymeras
sinc
rsv
replic
primarili
superfici
layer
respiratori
epithelium
local
deliveri
rnai
molecul
lung
ration
approach
inhibit
rsv
replic
studi
transittko
employ
transfect
agent
sirna
administ
lung
balbc
mice
intranas
instil
h
viral
challeng
rsv
piv
titer
reduc
five
day
infect
use
nake
sirna
also
show
substanti
inhibit
infect
approxim
effici
achiev
compar
complex
sirna
interestingli
administr
sirna
concomit
rsv
infect
effect
reduc
viral
load
treatment
infect
prophylact
regimen
may
clinic
attract
approach
achiev
optim
therapeut
benefit
fast
detect
earli
intervent
crucial
prognosi
rsv
infect
desir
initi
antivir
rnai
therapi
quickli
possibl
rsv
infect
confirm
clinic
practic
p
protein
may
ideal
target
limit
specif
particular
viral
strain
anoth
sirna
design
target
highli
conserv
region
mrna
encod
viral
nucleocapsid
protein
n
protein
n
protein
core
protein
rna
polymeras
play
key
role
replic
cycl
rsv
intranas
administr
lung
mous
h
prior
viral
infect
reduct
viral
load
observ
comparison
mismatch
sirna
control
treatment
regimen
compar
antivir
efficaci
achiev
multipl
daili
dose
day
postinfect
phase
clinic
studi
report
intranas
administr
well
toler
side
effect
profil
similar
placebo
later
antivir
effect
evalu
phase
ii
trial
administ
nasal
spray
daili
healthi
adult
two
day
three
day
rsv
inocul
group
treat
significantli
lower
number
rsv
infect
compar
placebo
group
anoth
phase
ii
b
clinic
trial
rsvinfect
lung
transplant
patient
also
complet
primari
endpoint
studi
evalu
effect
incid
new
progress
bronchiol
obliteran
syndrom
bo
rsvinfect
lung
transplant
patient
even
though
studi
margin
miss
primari
endpoint
statist
p
inhal
treatment
induc
clinic
meaning
reduct
incid
bo
reinforc
potenti
inhal
rnai
new
antivir
therapeut
season
influenza
virus
especi
influenza
type
viru
caus
annual
epidem
led
million
death
worldwid
one
major
public
health
problem
two
categori
antivir
drug
current
approv
treat
influenza
includ
ionchannel
protein
inhibitor
adamantan
neuraminidas
inhibitor
zanamivir
oseltamivir
howev
influenza
viru
strain
shown
resist
drug
make
develop
new
antivir
drug
urgent
need
number
studi
carri
investig
use
rnai
inhibit
viral
gene
express
protect
cell
influenza
infect
commonli
investig
target
nucleocapsid
protein
np
polymeras
acid
protein
pa
polymeras
basic
protein
pb
protein
indispens
influenza
viral
replic
importantli
highli
conserv
across
differ
subtyp
influenza
viru
strain
first
anim
studi
appli
rnai
influenza
report
ge
et
al
sirna
target
np
pa
complex
pei
complex
inject
intraven
mice
h
h
influenza
viru
infect
antivir
effect
sirna
target
np
dosedepend
combin
sirna
target
np
pa
enhanc
effect
studi
shrna
target
np
pb
also
investig
dna
mix
infasurf
commerci
avail
pulmonari
surfact
intranas
instil
signific
reduct
viru
titer
detect
h
infect
although
effect
less
promin
compar
intraven
inject
pei
complex
infasurf
may
play
role
nucleic
acid
carrier
littl
known
interact
dna
pulmonari
surfact
airspac
could
possibl
dna
interact
charg
lipid
compon
pulmonari
surfact
lead
effici
spread
absorpt
airway
anoth
studi
report
administr
sirna
target
np
andor
pa
lipid
carrier
influenzainfect
mice
hydrodynam
inject
intranas
administr
combin
sirna
deliveri
method
effect
protect
anim
lethal
challeng
highli
pathogen
avian
influenza
virus
includ
subtyp
sinc
potenti
sirna
treatment
influenza
viru
infect
continu
evalu
vitro
vivo
howev
explor
rnai
treatment
influenza
appear
reach
bottleneck
could
partli
attribut
critic
antivir
effect
induc
sirna
due
innat
immun
respons
rather
viral
inhibit
rnai
develop
chemic
modifi
rnai
molecul
minim
immunostimulatori
effect
could
help
delin
mechan
antivir
effect
tuberculosi
tb
bacteri
lung
infect
caus
mycobacterium
tuberculosi
mtb
emerg
multidrugresist
mdr
extens
drugresist
xdr
tb
slow
develop
new
antitb
agent
ineffici
vaccin
tb
still
major
global
health
problem
report
million
peopl
suffer
tb
million
die
annual
diseas
new
effect
tb
therapeut
highli
sought
approach
rnaibas
therapeut
tb
aim
modul
gene
express
host
instead
bacillu
bacteria
contain
requisit
machineri
rnai
current
rnai
investig
tb
treatment
two
direct
target
host
factor
essenti
surviv
mycobacteria
ii
modul
host
immun
respons
facilit
elimin
mycobacterium
autophagi
host
defens
mechan
mtb
boost
autophagi
could
effect
strategi
promot
erad
mycobacteria
henc
number
host
factor
involv
regul
autophagi
explor
target
rnai
includ
ra
homologu
enrich
brain
rheb
uv
radiat
resistanceassoci
gene
uvrag
downregul
factor
promot
autophagosom
format
reduc
bacteri
growth
howev
exist
studi
use
rnai
suppress
host
factor
preliminari
vivo
data
lack
moreov
recent
report
autophagi
pathway
may
essenti
restrict
mtb
growth
investig
requir
understand
relationship
mtb
infect
autophagi
pathway
better
posit
approach
rnai
control
tuberculosi
infect
anoth
strategi
modul
host
immun
respons
improv
antimicrobi
abil
host
one
key
characterist
tb
infect
format
granuloma
compact
organ
aggreg
immun
cell
granuloma
previous
consid
hostprotect
structur
sequest
infect
mycobacteria
recent
work
reveal
pathogen
could
take
advantag
granuloma
format
facilit
prolifer
dissemin
host
provid
hospit
environ
mycobacteria
surviv
replic
long
period
time
complic
chemokin
cytokin
network
involv
granulomat
respons
rnai
use
target
immunosuppress
cytokin
order
inhibit
growth
mtb
among
tumor
necrosi
factor
tnf
critic
activ
macrophag
trigger
format
granuloma
lymphotactin
chemokin
produc
activ
cell
chronic
tb
infect
suggest
regul
product
cell
contribut
stabil
granuloma
singl
dose
sirna
target
deliv
lung
mice
chronic
infect
tb
express
effect
inhibit
suppress
express
lung
associ
decreas
number
lymphocyt
reduct
respons
disorgan
granulomat
lesion
higher
fibrosi
although
inhibit
effect
elicit
sirna
transient
provid
signific
therapeut
benefit
proofofconcept
studi
demonstr
localenviron
immunopatholog
lung
modul
favor
host
respons
via
pulmonari
deliveri
sirna
target
rnaibas
immunotherapi
includ
transform
growth
factor
interleukin
found
elev
tb
patient
high
level
express
connect
tb
reactiv
chronic
infect
cytokin
restrain
inflamm
affect
helper
cell
h
respons
macrophag
activ
lead
substanti
reduct
antimicrobi
activ
studi
sirna
target
administ
intrapulmonari
rout
knockout
mice
day
postinfect
gene
silenc
result
increas
express
antimicrobi
mediat
nitric
oxid
induc
nitric
oxid
synthas
ino
significantli
reduc
bacteri
load
least
four
week
treatment
synergist
effect
improv
antimicrobi
activ
lung
observ
target
simultan
although
inhibit
bacteri
load
studi
modest
show
sirna
immunotherapi
feasibl
approach
enhanc
host
antimicrobi
capac
moreov
mdr
xdr
tb
pose
huge
challeng
current
chemotherapeut
agent
combin
immunotherapi
target
immunosuppress
cytokin
chemotherapi
target
drug
resist
bacteria
popul
direct
worth
futur
investig
respiratori
inflammatori
diseas
impos
substanti
healthcar
burden
worldwid
mani
patient
inadequ
control
current
therapi
diseas
character
inflamm
respiratori
tract
manifest
increas
express
inflammatori
cytokin
chemokin
common
lung
inflammatori
diseas
includ
asthma
chronic
obstruct
pulmonari
diseas
copd
acut
lung
injuri
ali
tabl
list
major
vivo
studi
examin
effect
rnai
molecul
respiratori
inflammatori
diseas
note
ahr
airway
hyperrespons
ali
acut
lung
injuri
balf
bronchoalveolar
lavag
fluid
cluster
differenti
ckit
stem
cell
factor
receptor
dc
dendrit
cell
high
mobil
group
peptid
ifu
infecti
unit
lp
lipopolysaccharid
mpl
myeloprolif
leukemia
viru
oncogen
ova
ovalbumin
argininerich
peptid
receptorinteract
protein
rsv
respiratori
syncyti
viru
lyas
soc
suppressor
cytokin
signal
protein
signal
transduc
activ
transcript
factor
syk
spleen
tyrosin
kinas
tfpei
transferrin
polyethylenimin
h
helper
cell
tumor
necrosi
vegfr
vascular
endotheli
growth
factor
asthma
character
variabl
revers
airflow
obstruct
airway
hyperrespons
ahr
mucu
hypersecret
chronic
inflamm
common
form
asthma
allerg
asthma
trigger
environment
stimuli
hous
dust
season
pollen
accord
estim
around
million
peopl
asthma
worldwid
mainstay
treatment
asthma
corticosteroid
adrenerg
receptor
agonist
leukotrien
receptor
antagonist
either
alon
combin
although
medic
manag
condit
patient
still
challeng
poor
patient
complianc
intoler
long
term
advers
effect
persist
allerg
asthmat
patient
omalizumab
antiimmunoglobulin
e
ige
monoclon
antibodi
use
high
cost
parenter
administr
make
less
favor
altern
antiinflammatori
drug
need
mani
inflammatori
mediat
identifi
involv
pathogenesi
asthma
investig
potenti
target
rnai
therapi
includ
cytokineschemokin
transcript
factor
tyrosin
kinasestyrosin
kinas
receptor
costimulatori
molecul
allerg
asthma
predomin
activ
helper
h
celldriven
inflammatori
respons
cell
activ
h
cytokin
express
increas
airway
atop
asthma
patient
exposur
allergen
h
cytokin
main
player
patholog
allerg
airway
inflamm
contribut
allerg
sensit
ige
product
eosinophil
infiltr
ahr
respect
clinic
studi
examin
therapeut
potenti
use
monoclon
antibodi
mab
neutral
bioactiv
target
receptor
progress
similarli
rnai
technolog
employ
target
cytokin
target
suppressor
cytokin
signal
soc
altern
approach
soc
protein
neg
regul
cytokin
signal
pathway
involv
h
cell
mediat
allerg
respons
via
control
balanc
h
h
cell
express
patholog
marker
allerg
diseas
sirna
target
intranas
administ
lung
chronic
asthmat
mous
model
silenc
downregul
express
h
cell
associ
cytokin
lead
substanti
reduct
airway
inflamm
ahr
well
ige
product
reduct
mucu
secret
collagen
deposit
also
detect
airway
besid
h
cell
cell
subset
h
h
cell
also
contribut
inflammatori
respons
asthma
releas
molecul
may
also
potenti
target
rnai
therapi
furthermor
combin
inflammatori
antivir
sirna
prospect
therapi
patient
virusinduc
exacerb
sever
uncontrol
asthma
view
report
respiratori
viral
infect
relat
asthma
exacerb
children
adult
therapeut
potenti
target
p
protein
rsv
simultan
sirna
examin
mous
model
rsvinduc
asthma
exacerb
intranas
deliveri
two
sirna
abl
significantli
suppress
mrna
express
rsv
replic
lung
ii
reduc
eosinophil
neutrophil
infiltr
bronchoalveolar
lavag
fluid
balf
iii
inhibit
ahr
inflamm
iv
increas
interferon
ifn
express
mani
transcript
factor
includ
nuclear
signal
transduc
activ
transcript
factor
gatabind
protein
involv
product
h
cytokin
airway
patient
asthma
investig
target
rnai
manag
asthmat
inflamm
play
key
role
express
mani
proinflammatori
protein
inhibit
pathway
lung
report
benefici
asthma
model
one
approach
inhibit
activ
signal
pathway
target
receptorinteract
protein
transcript
product
activ
suppress
express
achiev
mice
intratrach
deliveri
sirna
result
inhibit
ovalbumin
ova
induc
cytokin
releas
inflammatori
cell
infiltr
mucu
hypersecret
serum
ige
level
result
suggest
could
novel
therapeut
target
treatment
asthma
consist
find
suppress
murin
model
allergeninduc
asthma
rnai
significantli
inhibit
express
downstream
h
cytokin
studi
support
hypothesi
use
rnai
molecul
target
transcript
factor
manag
airway
inflamm
ahr
asthma
tyrosin
kinas
broadli
classifi
receptor
nonreceptor
type
play
import
role
activ
transcript
factor
inflammatori
gene
express
upon
activ
inflammatori
signal
key
receptor
tyrosin
kinas
involv
inflammatori
respons
asthma
includ
epiderm
growth
factor
receptor
egfr
ckit
stem
cell
factor
receptor
vascular
endotheli
growth
factor
receptor
vegfr
nonreceptor
form
spleen
tyrosin
kinas
syk
src
janu
kinas
jak
syk
pivot
intracellular
signal
molecul
involv
activ
sever
proinflammatori
transcript
factor
inhibit
syk
express
antisens
oligonucleotid
proven
effect
suppress
tracheal
contract
pulmonari
inflamm
anim
model
ovainduc
asthma
nake
sirna
target
syk
administ
lung
allergeninduc
asthma
mice
model
via
nasal
instil
recruit
inflammatori
cell
balf
reduc
similarli
intranas
administr
sirna
target
ckit
also
induc
promis
result
reduc
mucu
secret
airway
inflamm
experiment
asthma
mous
model
moreov
clinic
studi
perform
sirna
target
syk
develop
zabecor
pharmaceut
usa
treatment
asthma
phase
studi
asthma
patient
receiv
inhal
consecut
day
show
improv
breath
reduc
usag
rescu
inhal
compar
placebo
drug
well
toler
patient
without
elicit
seriou
side
effect
phase
ii
clinic
trial
initi
result
yet
avail
prepar
review
target
dendrit
cell
dc
airway
rnai
anoth
strategi
treatment
asthma
dc
antigen
present
cell
could
found
airway
activ
involv
differenti
h
cell
henc
contribut
progress
airway
inflamm
dc
express
costimulatori
molecul
cluster
differenti
cd
surfac
bind
cytotox
lymphocyteassoci
molecul
cell
necessari
prime
naiv
cell
h
cell
block
andor
activ
pharmacolog
inhibitor
inhibit
cell
activ
allevi
ahr
pulmonari
inflamm
mice
expos
aerosol
allergen
challeng
likewis
intratrach
administr
sirna
target
significantli
reduc
express
airway
mucosa
mous
model
allerg
asthma
sirna
treatment
also
contribut
amelior
ovainduc
airway
eosinophilia
hyperrespons
elev
ige
sera
product
inflammatori
cytokin
balf
copd
persist
lung
diseas
character
irrevers
chronic
airflow
limit
diseas
usual
progress
associ
increas
chronic
inflammatori
respons
lung
result
long
term
exposur
air
pollut
usual
associ
cigarett
smoke
affect
around
popul
world
fourth
lead
caus
death
industri
countri
expect
becom
third
three
class
medic
use
manag
copd
bronchodil
includ
adrenerg
receptor
anticholinerg
drug
corticosteroid
inhibitor
effect
reliev
symptom
copd
none
revers
progress
deterior
lung
function
cure
diseas
desir
develop
novel
therapi
simultan
control
symptom
improv
longterm
prognosi
diseas
despit
similar
clinic
featur
mechan
underli
airway
inflamm
asthma
copd
differ
distinct
pattern
inflammatori
cell
mediat
involv
mechan
mediat
drive
progress
chronic
inflamm
emphysema
copd
far
fulli
understood
major
signal
factor
involv
pathogenesi
copd
includ
vegf
mani
cytokin
chemokin
secret
airway
copd
patient
modul
pathway
therefor
rnai
target
pathway
strategi
manag
copd
current
research
work
rnai
therapi
copd
remain
mainli
vitro
stage
like
due
insuffici
understand
highli
complex
mechan
underli
patholog
diseas
moreov
degre
airway
inflammatori
respons
determin
genet
epigenet
factor
sinc
multipl
inflammatori
mediat
involv
diseas
process
block
singl
type
molecul
unlik
exert
signific
clinic
impact
mirna
advantag
target
multipl
gene
simultan
involv
regul
inflammatori
process
copd
modul
transcript
translat
gene
differenti
express
sever
mirna
like
identifi
copd
patient
compar
subject
without
copd
modul
express
multipl
gene
use
mirna
could
direct
rnai
therapi
treatment
copd
ali
sever
form
diffus
lung
diseas
commonli
caus
acut
system
inflammatori
disord
sepsi
pneumonia
trauma
pancreat
progress
diseas
lead
acut
respiratori
distress
syndrom
ard
critic
multipl
organ
failur
even
death
patholog
chang
includ
releas
proinflammatori
cytokin
chemokin
destruct
epitheliumcapillari
interfac
latter
facilit
extravas
proteinrich
fluid
infiltr
neutrophil
therebi
exacerb
condit
sinc
molecular
mechan
underli
patholog
ali
well
understood
pathophysiologicdriven
therapeut
approach
avail
rnai
target
essenti
inflammatori
mediat
could
offer
protect
progress
diseas
vivo
studi
system
deliveri
sirna
target
significantli
reduc
express
lung
lung
injuri
shockinduc
ali
mous
model
find
suggest
pulmonari
vascular
cell
epitheli
cell
contribut
releas
lead
lung
injuri
follow
system
inflammatori
insult
although
find
contradictori
other
suggest
pulmonari
epitheli
cell
major
player
caus
lung
injuri
induc
system
diseas
nevertheless
provid
evid
support
use
sirna
target
manag
ali
increas
microvascular
permeabl
major
caus
amplif
inflammatori
respons
ali
lead
progress
sever
patholog
condit
integr
pulmonari
system
endotheli
barrier
maintain
bioactiv
lipid
irrevers
degrad
enzym
call
lyas
therefor
suppress
endotheli
express
sirna
potenti
therapeut
approach
maintain
integr
endotheli
barrier
nanoparticl
contain
sirna
target
recombin
high
mobil
group
peptid
deliv
lung
lpsinduc
ali
mous
model
intratrach
instil
peptid
antagonist
proinflammatori
cytokin
provid
addit
antiinflammatori
effect
ali
argininerich
peptid
use
carrier
level
significantli
inhibit
balf
lead
significantli
reduct
inflammatori
cytokin
inflammatori
respons
lung
treat
anim
although
sever
vivo
studi
demonstr
promis
result
use
rnai
therapeut
manag
respiratori
inflammatori
diseas
sever
concern
need
taken
consider
approach
distribut
nake
sirna
follow
intranas
intratrach
administr
investig
shown
sirna
molecul
predominantli
accumul
peribronchi
epitheli
cell
within
h
postadministr
sinc
inflammatori
mechan
diseas
like
asthma
appear
driven
activ
h
lymphocyt
highli
desir
rnai
molecul
target
activ
cell
airway
achiev
therapeut
benefit
howev
specif
target
cell
extrem
difficult
effect
cell
transfect
vitro
achiev
electropor
approach
clinic
feasibl
recent
ligandpolym
conjug
sirna
deliveri
system
transferrinpolyethylenimin
tfpei
develop
target
cell
lung
ration
design
base
increas
express
transferrin
receptor
cell
activ
biodistribut
studi
show
tfpei
polyplex
select
deliv
fluoresc
label
sirna
activ
cell
murin
asthma
model
howev
therapeut
effect
system
evalu
therefor
target
deliveri
rnai
therapeut
specif
cell
type
associ
diseas
field
certainli
requir
explor
key
signal
molecul
involv
pathogenesi
respiratori
inflammatori
disord
multipl
function
particip
normal
physiolog
activ
maintain
homeostasi
shortterm
regimen
four
day
employ
major
anim
studi
durat
treatment
may
suffici
observ
longterm
effect
sinc
mani
inflammatori
diseas
chronic
disord
longterm
therapi
often
requir
control
diseas
therefor
crucial
evalu
longterm
effect
rnai
therapeut
inhal
corticosteroid
commonli
use
control
symptom
lung
inflammatori
disord
steroid
treatment
reduc
airway
inflamm
partial
downregul
key
effector
molecul
ckit
reason
necessari
determin
effect
concurr
medic
express
target
molecul
initi
rnai
therapi
given
lung
inflammatori
diseas
heterogen
diseas
categor
differ
subtyp
accord
inflammatori
profil
respons
treatment
desir
identifi
patient
profil
order
maxim
benefit
rnai
therapi
pulmonari
fibrosi
respiratori
disord
character
progress
irrevers
destruct
lung
architectur
ultim
lead
organ
malfunct
disrupt
ga
exchang
even
death
initi
lung
tissu
damag
result
autoimmun
disord
exposur
extern
irrit
damag
turn
trigger
inflammatori
reaction
tissu
repair
attempt
restor
normal
tissu
architectur
function
patholog
condit
extracellular
matrix
ecm
compon
releas
activ
myofibroblast
wound
heal
process
excess
produc
accumul
site
tissu
injuri
result
fibrosi
mani
form
pulmonari
fibrosi
lethal
diseas
high
mortal
rate
limit
therapeut
option
thu
pulmonari
fibrosi
lung
diseas
huge
unmet
medic
need
rnai
exploit
suppress
product
key
molecul
involv
fibrot
process
amphiregulin
ar
connect
transform
growth
factor
ctgf
tabl
clinic
trial
examin
effect
neutral
antibodi
block
activ
current
ongo
sinc
lung
epitheli
cell
key
cell
type
pathogenesi
pulmonari
fibrosi
local
administr
rnai
target
lung
ensur
high
local
concentr
rnai
molecul
produc
therapeut
effect
intratrach
deliveri
sirna
target
could
effect
inhibit
pulmonari
fibrosi
improv
lung
function
prolong
surviv
human
transgen
mice
anoth
vivo
studi
intranas
deliveri
mimic
design
suppress
express
profibrot
gene
significantli
reduc
express
level
allevi
fibrot
featur
bleomycininduc
pulmonari
fibrosi
result
suggest
potenti
target
signal
pathway
use
rnai
technolog
manag
lung
fibrosi
note
ar
amphiregulin
chemokin
cc
motif
ligand
chemoattract
ctgf
connect
tissu
growth
factor
pdgf
plateletderiv
growth
factor
pdmaema
poli
dimethylamino
ethylmethacryl
pmapeg
poli
methylethermethacrylateethyleneglycol
samirna
selfassembl
micel
interf
rna
transform
growth
factor
one
complic
use
molecular
target
rnai
relat
physiolog
role
maintain
immun
cellular
homeostasi
role
tumor
suppress
suggest
find
specif
inhibit
mous
stromal
fibroblast
result
spontan
carcinoma
format
adjac
epithelium
result
target
downstream
effector
may
offer
therapeut
benefit
inhibit
fibrot
respons
preserv
major
physiolog
function
profibrot
cytokin
ctgf
key
molecul
regul
fibroblast
mitosi
promot
collagen
deposit
pulmonari
fibrosi
induc
nonvir
deliveri
system
consist
poli
dimethylamino
ethylmethacryl
pdmaema
copolym
poli
methylethermethacrylateethyleneglycol
pmapeg
use
incorpor
form
complex
sirna
target
ctgf
intratrach
administr
signific
reduct
ctgf
express
collagen
deposit
inflammatori
cytokin
product
observ
bleomycininduc
lung
fibrosi
anim
model
importantli
surviv
rate
anim
treat
sirna
target
ctgf
significantli
increas
comparison
group
treat
scrambl
sirna
anoth
downstream
mediat
amphiregulin
ar
epiderm
growth
factor
receptor
egfr
ligand
primarili
induc
sirna
target
ar
ctgf
deliv
lung
pulmonari
fibrosi
mous
model
via
either
intratrach
intraven
administr
improv
effici
cellspecif
deliveri
modifi
selfassembl
micel
interf
rna
nanoparticl
samirna
develop
nanoparticl
contain
hydrophil
polym
hydrophob
lipid
end
sirna
spontan
form
micel
solut
administr
ar
ctgf
samirna
express
ar
ctgf
collagen
accumul
lung
pulmonari
fibrosi
model
significantli
reduc
compar
control
samirna
rnai
technolog
rapid
develop
last
decad
therapeut
potenti
rnai
molecul
airway
diseas
demonstr
sever
clinic
studi
tabl
could
solut
unmet
medic
need
rnai
therapeut
gain
approv
regulatori
author
time
manuscript
prepar
deliveri
gener
consid
major
obstacl
rnai
therapeut
develop
interest
notic
sirna
mirna
mimic
need
carrier
gener
therapeut
effect
follow
pulmonari
deliveri
cellular
uptak
mechan
nake
rna
airway
clear
certainli
attract
featur
allow
simpl
formul
without
need
deliveri
vector
chemic
modifi
sirna
mirna
necessari
improv
stabil
rna
molecul
hand
deliveri
shrna
mirna
encod
plasmid
requir
viral
vector
ensur
effici
transduct
subsequ
express
rnai
molecul
howev
use
viral
vector
could
rais
safeti
concern
clinic
applic
especi
use
pulmonari
deliveri
employ
liposom
polym
base
nanoparticl
deliveri
technolog
could
promis
approach
whether
nanoparticl
nake
rna
use
import
evalu
pharmacokinet
profil
deliveri
system
ensur
rnai
therapeut
local
site
action
quickli
distribut
organ
bodi
term
formul
rnai
therapeut
dri
powder
aerosol
prefer
liquid
aerosol
due
higher
stabil
dri
powder
inhal
easier
oper
better
lung
deposit
would
direct
rnai
formul
develop
among
differ
type
rnai
molecul
therapeut
develop
sirna
made
signific
progress
coupl
clinic
studi
investig
pulmonari
deliveri
sirna
treat
respiratori
diseas
also
grow
number
clinic
pipelin
involv
use
sirna
rnai
molecul
sever
key
question
rais
need
answer
infecti
diseas
demonstr
sever
vivo
studi
appear
rnai
effect
prophylact
regimen
therapeut
regimen
improv
therapeut
efficaci
rnai
combat
infect
make
clinic
relev
inflammatori
diseas
longterm
therapi
expect
minim
undesir
effect
cytokineschemokin
target
respiratori
function
compromis
patient
lung
diseas
pulmonari
deliveri
suitabl
rout
administr
complic
signal
pathway
involv
pathogenesi
differ
lung
disord
thorough
investig
underli
patholog
mechan
diseas
prerequisit
identifi
target
rnai
despit
challeng
obstacl
believ
pulmonari
deliveri
rnai
molecul
target
airway
diseas
promis
